Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF

TRIM24 is a transcriptional regulator as well as an E3 ubiquitin ligase. It is overexpressed in diverse tumors, and high expression levels have been linked to poor prognosis in breast cancer patients. TRIM24 contains a PHD/bromodomain offering the opportunity to develop protein interaction inhibitors that target this protein interaction module. Here we identified potent acetyl-lysine mimetic benzimidazolones TRIM24 bromodomain inhibitors. The best compound of this series is a selective BRPF1B/TRIM24 dual inhibitor that bound with a KD of 137 and 222 nM, respectively, but exerted good selectivity over other bromodomains. Cellular activity of the inhibitor was demonstrated using FRAP assays as well as cell viability data.

[1]  Zhen-ning Wang,et al.  TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance , 2015, Virchows Archiv.

[2]  Lewis R. Vidler,et al.  Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B , 2015, Journal of medicinal chemistry.

[3]  Hua Yu,et al.  Knockdown of Tripartite Motif Containing 24 by Lentivirus Suppresses Cell Growth and Induces Apoptosis in Human Colorectal Cancer Cells , 2014, Oncology research.

[4]  S. Carr,et al.  Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer , 2014, Science.

[5]  David J. Fallon,et al.  1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. , 2014, ACS medicinal chemistry letters.

[6]  Parantu K. Shah,et al.  TRIM24 links glucose metabolism with transformation of human mammary epithelial cells , 2014, Oncogene.

[7]  A. Gingras,et al.  Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching , 2014, Epigenetics & Chromatin.

[8]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[9]  Stefan Knapp,et al.  A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation–π Interaction** , 2014, Angewandte Chemie.

[10]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[11]  John L Markley,et al.  Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. , 2014, Journal of molecular biology.

[12]  L. Wodicka,et al.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.

[13]  S. Olesen,et al.  Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors , 2014, ACS chemical biology.

[14]  Jin-xiang Cheng,et al.  TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway , 2014, Oncogene.

[15]  Yu Huang,et al.  Overexpression of TRIM24 Is Associated with the Onset and Progress of Human Hepatocellular Carcinoma , 2014, PloS one.

[16]  S. Knapp,et al.  [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains , 2013, Journal of medicinal chemistry.

[17]  S. Knapp,et al.  Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening , 2013, Journal of medicinal chemistry.

[18]  S. Knapp,et al.  PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.

[19]  L. Mao,et al.  TRIM24 Overexpression Is Common in Locally Advanced Head and Neck Squamous Cell Carcinoma and Correlates with Aggressive Malignant Phenotypes , 2013, PloS one.

[20]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[21]  Stefan Knapp,et al.  The bromodomain interaction module , 2012, FEBS letters.

[22]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[23]  Ying Xu,et al.  Overexpression of TRIM24 Correlates with Tumor Progression in Non-Small Cell Lung Cancer , 2012, PloS one.

[24]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[25]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[26]  Stefan Knapp,et al.  Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.

[27]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[28]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[29]  D. Patel,et al.  TRIM24 links a noncanonical histone signature to breast cancer , 2010, Nature.

[30]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[31]  J. Qin,et al.  Trim24 targets endogenous p53 for degradation , 2009, Proceedings of the National Academy of Sciences.

[32]  Jessica Zucman-Rossi,et al.  Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha , 2007, Nature Genetics.

[33]  F. Jeanmougin,et al.  A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. , 1996, The EMBO journal.

[34]  Stefan Knapp,et al.  Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.